Related Experiment Video
Updated: May 23, 2026
07:42
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
A population-based study on dementia and stroke in 97 year olds
Mats Andersson1, Xinxin Guo, Anne Börjesson-Hanson
1Neuropsykiatri, Neuropsychiatric Epidemiology, Wallinsgatan 6, SU/Mölndal SE-431 41, Sweden. mats.andersson@neuro.gu.se
Age and Ageing
|March 21, 2012
Summary
Dementia is highly prevalent in 97-year-olds and linked to mortality and institutionalization. Stroke/transient ischemic attack (TIA) showed less association with these outcomes in this age group compared to younger populations.
Area of Science:
- Gerontology
- Neurology
- Epidemiology
Background:
- The global nonagenarian population is rapidly increasing.
- Understanding health conditions in extreme old age is crucial.
Purpose of the Study:
- To determine the prevalence of stroke/transient ischemic attack (TIA) and dementia in 97-year-olds.
- To investigate the relationship between stroke/TIA and dementia.
- To assess the association of these conditions with mortality and institutionalization over two years.
Main Methods:
- A population-based study of 591 individuals aged 97.
- Stroke/TIA data collected via self-reports, key informants, and hospital records.
- Dementia diagnosed using DSM-III-R criteria.
Main Results:
- Dementia prevalence was 32.7% in men and 59.3% in women.
- Stroke/TIA prevalence was 21.5% overall.
- Stroke/TIA associated with dementia in women (OR=1.9), but not men.
- Dementia, not stroke/TIA, predicted 2-year mortality and institutionalization.
Conclusions:
- Dementia is common in nonagenarians and significantly impacts mortality and institutionalization.
- Stroke/TIA had a weaker association with dementia and adverse outcomes in 97-year-olds than in younger populations.
- Further research is needed to understand dementia etiology in nonagenarians.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...